Bio Roundup: Theranos Cuts, Alnylam Stops, Nobel Eats Its Own & More
Xconomy
OCTOBER 7, 2016
coast bearing the brunt of Hurricane Matthew, we send our thoughts and more to those who have more pressing matters to worry about this week. —Merrimack Pharmaceuticals (NASDAQ: MACK ) announced layoffs of 22 percent of its staff and the resignation of CEO Robert Mulroy. With the Caribbean and now the southeast U.S.
Let's personalize your content